ArticleOcular oncology and pathology2026
Pars Plana Vitrectomy for Retinal Detachment or Vitreous Haemorrhage after Retinoblastoma Regression: A 20-Year Single-Centre Experience.
Article in Ocular oncology and pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intraocular surgery for retinoblastoma has traditionally been performed carefully because of the risk of tumour spread. However, some eyes with proven tumour regression can develop rhegmatogenous retinal detachment or dense vitreous haemorrhage. We report a 20-year single-centre experience with pars plana vitrectomy in eyes previously treated for retinoblastoma. Methods: We reviewed cases from a single centre in which children with treated retinoblastoma underwent pars plana vitrectomy for retinal detachment or dense non-clearing vitreous haemorrhage between January 2003 and October 2022. Surgery followed a local oncologic safeguard checklist, Q-TRICS, incorporating documented quiescence, trajectory-safe ports, port-site triple freeze-thaw cryotherapy, intravitreal chemotherapy at closure, silicone oil tamponade, and readiness to enucleate if tumour activity was suspected. Early surgeries used 20-23-gauge Accurus systems, whereas later surgeries used 23-25-gauge Constellation platforms, with intravitreal topotecan administered at the time of closure. Results: This study included nine children. On average, they were 67.6 months old at the time of vitrectomy, and the average interval from the last retinoblastoma-directed therapy to retinal detachment or vitreous haemorrhage was 34.3 months. Seven eyes underwent surgery for retinal detachment, and two had dense vitreous haemorrhage. The median follow-up was 3 years. By the last follow-up, eight out of nine eyes had complete retinal reattachment. Three eyes improved their visual acuity by at least 1.0 logMAR, and four eyes reached a final best-corrected visual acuity of 6/60 or better. There were no cases of tumour recurrence, extraocular extension, metastasis, or secondary malignancy during the follow-up. Conclusion: Pars plana vitrectomy was associated with high anatomical success in this small, highly selected series of eyes with regressed retinoblastoma, with no observed intraocular recurrence, extraocular extension, metastasis, or secondary malignancy during the available follow-up period. Although functional recovery was limited, it occurred more frequently in the modern micro-incision, closure-time topotecan era. Larger, multicentre studies with standardised follow-up and toxicity monitoring are necessary to define residual oncologic risk further and establish optimal surgical safeguards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.